These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Whole exome sequencing identifies novel mutations of epigenetic regulators in chemorefractory pediatric acute myeloid leukemia. Zhan D; Zhang Y; Xiao P; Zheng X; Ruan M; Zhang J; Chen A; Zou Y; Chen Y; Huang G; Hu S; Wang QF; Zhu X Leuk Res; 2018 Feb; 65():20-24. PubMed ID: 29253671 [TBL] [Abstract][Full Text] [Related]
11. Mutant U2AF1-Induced Mis-Splicing of mRNA Translation Genes Confers Resistance to Chemotherapy in Acute Myeloid Leukemia. Jin P; Wang X; Jin Q; Zhang Y; Shen J; Jiang G; Zhu H; Zhao M; Wang D; Li Z; Zhou Y; Li W; Zhang W; Liu Y; Wang S; Jin W; Cao Y; Sheng G; Dong F; Wu S; Li X; Jin Z; He M; Liu X; Chen L; Zhang Y; Wang K; Li J Cancer Res; 2024 May; 84(10):1583-1596. PubMed ID: 38417135 [TBL] [Abstract][Full Text] [Related]
12. [The Relationship between ASXL2 and ZBTB7A Gene Mutations and Prognosis in Patients with Acute Myeloid Leukemia]. Cao HQ; Tuo JB Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):450-455. PubMed ID: 33812414 [TBL] [Abstract][Full Text] [Related]
13. Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia. Long L; Assaraf YG; Lei ZN; Peng H; Yang L; Chen ZS; Ren S Drug Resist Updat; 2020 Sep; 52():100703. PubMed ID: 32599434 [TBL] [Abstract][Full Text] [Related]
14. Whole-exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia. Shiba N; Yoshida K; Shiraishi Y; Okuno Y; Yamato G; Hara Y; Nagata Y; Chiba K; Tanaka H; Terui K; Kato M; Park MJ; Ohki K; Shimada A; Takita J; Tomizawa D; Kudo K; Arakawa H; Adachi S; Taga T; Tawa A; Ito E; Horibe K; Sanada M; Miyano S; Ogawa S; Hayashi Y Br J Haematol; 2016 Nov; 175(3):476-489. PubMed ID: 27470916 [TBL] [Abstract][Full Text] [Related]
15. Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome. Li X; Xu F; Zhang Z; Guo J; He Q; Song LX; Wu D; Zhou LY; Su JY; Xiao C; Chang CK; Wu LY Clin Epigenetics; 2021 Aug; 13(1):169. PubMed ID: 34461985 [TBL] [Abstract][Full Text] [Related]
16. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Lindsley RC; Mar BG; Mazzola E; Grauman PV; Shareef S; Allen SL; Pigneux A; Wetzler M; Stuart RK; Erba HP; Damon LE; Powell BL; Lindeman N; Steensma DP; Wadleigh M; DeAngelo DJ; Neuberg D; Stone RM; Ebert BL Blood; 2015 Feb; 125(9):1367-76. PubMed ID: 25550361 [TBL] [Abstract][Full Text] [Related]
17. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199. Naqvi K; Konopleva M; Ravandi F Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432 [TBL] [Abstract][Full Text] [Related]
18. Expression of myeloid Src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistance. Patel RK; Weir MC; Shen K; Snyder D; Cooper VS; Smithgall TE PLoS One; 2019; 14(12):e0225887. PubMed ID: 31790499 [TBL] [Abstract][Full Text] [Related]
19. Analysis of nonleukemic cellular subcompartments reconstructs clonal evolution of acute myeloid leukemia and identifies therapy-resistant preleukemic clones. Saeed BR; Manta L; Raffel S; Pyl PT; Buss EC; Wang W; Eckstein V; Jauch A; Trumpp A; Huber W; Ho AD; Lutz C Int J Cancer; 2021 Jun; 148(11):2825-2838. PubMed ID: 33411954 [TBL] [Abstract][Full Text] [Related]
20. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]